Beximco Pharmaceuticals PLC. announcements
297 Dhaka Stock Exchange announcements for Beximco Pharmaceuticals PLC. (BXPHARMA) since 2007: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2021 (31).
- Credit Rating Information and Services Limited (CRISL) has rated the Company as \"AAA\" in the long term and \"ST-1\" in
Credit Rating Information and Services Limited (CRISL) has rated the Company as \"AAA\" in the long term and \"ST-1\" in the short term along with a stable outlook in consideration of its audited financials up to June 30, 2021, unaudited financials up to September 30, 2021 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
- Resumption after record date
Trading of the shares of the Company will resume on 23.11.2021 after record date.
- Suspension for Record date
Trading of the shares of the Company will remain suspended on record date i.e., 22.11.2021.
- Spot News
Trading of the shares of the Company will be allowed only in the Spot Market and Block transactions will also be settled as per Spot settlement cycle with cum benefit from 18.11.2021 to 21.11.2021. Trading of the shares of the Company will remain suspended on record date i.e., 22.11.2021.
- (Q1 Un-audited): Consolidated EPS was Tk. 3.28 for July-September 2021 as against Tk. 2.41 for July-September 2020; Cons
(Q1 Un-audited): Consolidated EPS was Tk. 3.28 for July-September 2021 as against Tk. 2.41 for July-September 2020; Consolidated NOCFPS was Tk. 4.46 for July-September 2021 as against Tk. 3.00 for July-September 2020. NAV per share was Tk. 86.31 as on September 30, 2021 and Tk. 82.78 as on September 30, 2020. (cont.)
- (Cont. of BXPHARMA): The Company achieved 22.3\% increase in sales in the reported first quarter as compared to the same
(Cont. of BXPHARMA): The Company achieved 22.3\% increase in sales in the reported first quarter as compared to the same period of prior year. Alongside gaining from the double-digit sales growth consistent to past p increase in sales in the reported first quarter as compared to the same period of prior year. Alongside gaining from the double-digit sales growth consistent to past periods, higher demand for the repurposed drugs for the Covid-19 treatment, (cont.)
The first part of this announcement is missing from the archive. - Q1 Financials
(Cont. of BXPHARMA): other medicines related to the treatment of Covid-19 patients and new products contributed to the attainment of sales growth. The earning per share and operating cash flows per share increased predominantly due to the increase in sales. (end)
The first part of this announcement is missing from the archive. - Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 11, 2021 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2021.
- Dividend Declaration
The Board of Directors has recommended 35% cash dividend for the year ended on June 30, 2021. Date of AGM: 23.12.2021, Time: 10:30 AM, Venue: Digital Platform. Record Date: 22.11.2021. The Company has also reported Consolidated EPS of Tk. 11.49, Consolidated NAV per share of Tk. 83.01 and Consolidated NOCFPS of Tk. 13.50 for the year ended on June 30, 2021 as against Tk. 7.88, Tk. 80.12 and Tk. 13.67 respectively for the same period of the previous year.
- Price Limit Open
There will be no price limit on the trading of the shares of the Company today (24.10.2021) following its corporate declaration.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 21, 2021 at 3:30 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2021.
- Completion of acquisition of a majority stake in Sanofi Bangladesh Ltd
Referring to their earlier news disseminated by DSE on 24.01.2021, 05.09.2021 and 14.09.2021 regarding acquisition of a majority stake in Sanofi Bangladesh Limited, the Company has further informed that they have now completed its acquisition of the majority stake in Sanofi Bangladesh Limited. The final consideration, payable in cash (post the closing adjustments previously outlined), was approximately BDT 469.62 crore (Equivalent pound 39.35 million).
- Refer to the earlier news disseminated by DSE on 24 January 2021 and 05 September 2021, the Company has further informed
Refer to the earlier news disseminated by DSE on 24 January 2021 and 05 September 2021, the Company has further informed that the company has now entered into the share purchase agreement to acquire the majority stake in Sanofi Bangladesh Limited ("Sanofi Bangladesh") (the "Acquisition"). The proposed earnings accretive Acquisition is in line with Beximco Pharma's strategy to expand its capabilities and product offering into new specialty therapy areas (Cont. 1)
- (Cont. of BXPHARMA): while enabling the Company to consolidate its position as a leading pharmaceutical in Bangladesh by
(Cont. of BXPHARMA): while enabling the Company to consolidate its position as a leading pharmaceutical in Bangladesh by adding an established business with a reputation for high-quality products. Sanofi Bangladesh has been part Sanofi SA ("Sanofi"), a global biopharmaceutical company focused on human health. The operations in Bangladesh were established in 1958 as part of the British chemical company, May & Baker. (Cont. 2)
The first part of this announcement is missing from the archive. - (Cont. of BXPHARMA): Following a series of mergers, it became known as Sanofi-Aventis in 2004, before being renamed in 2
(Cont. of BXPHARMA): Following a series of mergers, it became known as Sanofi-Aventis in 2004, before being renamed in 2013 as Sanofi Bangladesh Limited. Sanofi Bangladesh's state-of-the-art manufacturing facilities, including a PICIS certifiable manufacturing facility for the leading antibiotic, cephalosporin, are spread over c25 acres of land, located near Beximco Pharma's manufacturing facility in Tongi. (Cont. 3)
The first part of this announcement is missing from the archive. - (Cont. of BXPHARMA): Sanofi Bangladesh has over 800 employees and produces approximately 100 branded generic products, p
(Cont. of BXPHARMA): Sanofi Bangladesh has over 800 employees and produces approximately 100 branded generic products, predominately for the local market. Sanofi Bangladesh has a strong presence in cardiology, diabetes, oncology, dermatology and CNS. Sanofi also supplies its global brands of vaccines, insulins and chemotherapy drugs to Bangladesh through direct imports, which the Group will continue to distribute following the completion of the Acquisition. (Cont. 4)
The first part of this announcement is missing from the archive. - Share Purchase Agreement Signed
(Cont. of BXPHARMA): In the year ended 31 December 2020 (the last audited accounts prepared by Sanofi Bangladesh), Sanofi Bangladesh generated revenue of Taka 3.038 billion (approximately 25.8 million Pound), profit before tax of Taka 277.6 million (approximately 2.35 million Pound) and had gross assets of Taka 6.409 billion (approximately 54.4m Pound). A further announcement will be made in due course to confirm final completion of the Acquisition. (End)
The first part of this announcement is missing from the archive. - Refer to their earlier news disseminated by DSE on 24.01.2021 regarding proposed acquisition of a majority stake in Sano
Refer to their earlier news disseminated by DSE on 24.01.2021 regarding proposed acquisition of a majority stake in Sanofi Bangladesh Limited, the Company has further informed that the Company's proposed acquisition of a majority stake in Sanofi Bangladesh Limited ("Sanofi Bangladesh") has been approved by the Foreign Exchange Investment Department of Bangladesh Bank. (cont.)
- Sanofi Bangladesh acquisition approved by Bangladesh Bank
(Continuation news of BXPHARMA): As anticipated, the Company and the Vendor will now seek to execute the Share Purchase Agreement. Further announcements will be made in due course. (end)
The first part of this announcement is missing from the archive. - (Q3 Un-audited): Consolidated EPS was Tk. 3.28 for January-March 2021 as against Tk. 2.02 for January-March 2020; Consol
(Q3 Un-audited): Consolidated EPS was Tk. 3.28 for January-March 2021 as against Tk. 2.02 for January-March 2020; Consolidated EPS was Tk. 8.23 for July 2020-March 2021 as against Tk. 5.84 for July 2019-March 2020. Consolidated NOCFPS was Tk. 9.05 for July 2020-March 2021 as against Tk. 9.83 for July 2019-March 2020. Consolidated NAV per share was Tk. 79.73 as on March 31, 2021 and Tk. 77.88 as on March 31, 2020. The company has informed that increased in EPS predominantly from (Cont-1)
- (Continuation news of BXPHARMA) the organic growth of business and hence the profit, part of this attributable to the in
(Continuation news of BXPHARMA) the organic growth of business and hence the profit, part of this attributable to the income from Vaccine distribution and increased cash incentive from export. They also informed that they have entered into a tripartite agreement with the Government of Bangladesh (GOB) and the Serum Institute of India Pvt. Ltd. (SII), for the supply of 30 million doses of Oxford University-AstraZenca SARS-CoV-2 vaccine, AZD1222, in Bangladesh. The Company (Cont-2)
The first part of this announcement is missing from the archive. - (Continuation news of BXPHARMA) delivered 5 million vaccines during the reported quarter. As per agreement, the Company
(Continuation news of BXPHARMA) delivered 5 million vaccines during the reported quarter. As per agreement, the Company is to receive fees for import, storage and delivery of the vaccine to the GOB warehouses across the country. A net amount of BDT. 383.70 million after deduction of related expenses from fees, has been reported (Cont-3)
The first part of this announcement is missing from the archive. - (Continuation news of BXPHARMA) as Income from Vaccine Distribution: under the head Other Income. This is non-incurring
(Continuation news of BXPHARMA) as Income from Vaccine Distribution: under the head Other Income. This is non-incurring one off contract and any future earning from this source is dependent on the delivery of the committed quantity of vaccine under the agreement (end)
The first part of this announcement is missing from the archive. - Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Corporation has informed that a meeting of the Board of Directors will be held on April 29, 2021 at 2:30 PM to consider, among others, un-audited financial statements of the Corporation for the Third Quarter (Q3) period ended on March 31, 2021.
- Q2 Financials
(Q2 Un-audited): Consolidated EPS was Tk. 2.54 for October-December 2020 as against Tk. 1.89 for October-December 2019; Consolidated EPS was Tk. 4.95 for July-December 2020 as against Tk. 3.83 for July-December 2019. Consolidated NOCFPS was Tk. 4.91 for July-December 2020 as against Tk. 9.14 for July-December 2019. Consolidated NAV per share was Tk. 76.45 as on December 31, 2020 and Tk. 75.66 as on December 31, 2019.
- The Company has informed that Board of Directors of the company in their meeting held on January 21, 2021 at 2.30 PM dec
The Company has informed that Board of Directors of the company in their meeting held on January 21, 2021 at 2.30 PM decided to enter into a binding commitment with Sanofi Group regarding the acquisition of a majority stake in Sanofi Bangladesh Limited for a base-price consideration of circa Pound 35.5 million, to be adjusted as set out below (the Proposed Transaction). The Proposed Transaction is subject to approval by the Bangladesh Bank and completing the Share Purchase Agreement. (Cont.1)
- (Cont. News of BXPHARMA): The Proposed Transaction is for a total of 1,963,241 shares, representing approximately 54.6 P
(Cont. News of BXPHARMA): The Proposed Transaction is for a total of 1,963,241 shares, representing approximately 54.6 Percent of Sanofi Bangladesh's total share capital. Beximco Pharma was selected as the preferred bidder in a competitive process. The remaining 45.4 percent shares in Sanofi Bangladesh is owned by the Government of Bangladesh through Bangladesh Chemical Industries Corporation (approximately 20 percent) and the Ministry of Industries (approximately 25.4 percent). (Cont.2)
The first part of this announcement is missing from the archive. - (Cont. News of BXPHARMA): The base-price consideration of Pound 35.5 million is subject to deduction for the net financi
(Cont. News of BXPHARMA): The base-price consideration of Pound 35.5 million is subject to deduction for the net financial debt and adjustments for short or excess over an agreed normative working capital at the closing date. The final consideration, which may be up to a maximum of Pound 40 million, would be paid in cash on completion of the Proposed Transaction, from a combination of the Company's own cash resources and additional debt. (Cont.3)
The first part of this announcement is missing from the archive. - (Cont. News of BXPHARMA): It is anticipated that the Proposed Transaction will be completed within the next three to nin
(Cont. News of BXPHARMA): It is anticipated that the Proposed Transaction will be completed within the next three to nine months. If the Proposed Transaction is not approved by the Foreign Exchange Investment department of Bangladesh Bank, or has not completed by 20 October 2021, Sanofi would be able to withdraw in which case the Company's commitment would lapse and the Proposed Transaction would not proceed. (End)
The first part of this announcement is missing from the archive. - Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 27, 2021 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2020.
- Dividend Disbursement
The Company has informed that it has disbursed the cash dividend for the year ended on June 30, 2020 to the respective shareholders' Bank Accounts through BEFTN system.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.